Ask the payer's question early: MHRA-NICE's RWE dialogue is now an offer to use

A pilot that grew up

On 5 November the MHRA added application details and an expression-of-interest form for the newest cycle of its MHRA-NICE real-world evidence scientific dialogue. The records describe it as an established offer after a pilot. That is easy to read as housekeeping. I think it is the most useful thing in this week's market access news, and it deserves more attention than the larger announcements around it.

The reason is simple. Evidence plans are still mostly written for the regulator and then retrofitted for payers. A service run jointly by a regulator and an HTA body invites sponsors to test one real-world evidence question against both audiences at once, before data collection is locked.

The evidence questions keep moving after the decision

Look at what else crossed the desk. The Commission published the joint clinical assessment report on camizestrant (Etcamah), prepared by Austria and Belgium and endorsed by Member States on 19 August 2026. It will feed national decision-making. In Italy, AIFA revised several monitoring registries on 6 November. The Enhertu registries no longer block treatment of patients with active, symptomatic or uncontrolled brain metastases. The Rybrevant registries gained subcutaneous schedules. The Imfinzi neoadjuvant registry gained a carboplatin-gemcitabine option. A new registry opened for Voranigo.

None of this is a scandal. It shows that the populations, regimens and comparators payers care about shift after the first dossier. Sera Prognostics, meanwhile, reports Florida as the second state Medicaid programme to cover its PreTRM test while it begins a CE Mark submission for a kit-based version. Coverage and certification are accumulating body by body, each with its own questions.

Meanwhile CMS has finalised a permanent framework for Medicare drug price negotiation from 2029. Whatever your view of the policy, the direction is clear: evidence that supports value will be examined repeatedly and by different institutions. Aligning with them once, early, is cheaper than answering them one at a time.

The strongest counter-argument

The best objection is that a dialogue is only advice. The records do not say what the MHRA-NICE process produces or how binding it is, and nothing here suggests that a favourable conversation changes a later appraisal. The UK is also one market, and an EU team facing joint clinical assessments and national processes may reasonably ask whether UK-specific advice travels. Real-world evidence has its own credibility problems, and a well-designed question for one body can still miss another's.

Those points are fair, and I would not oversell the service. But they argue for using it with discipline, not for ignoring it. A non-binding conversation that exposes a flaw in your evidence design before the data exist costs little. The same flaw found at appraisal can cost a great deal. The records also do not give cycle timings, eligibility criteria or capacity, so the first job is to read the primary page.

Recommendation

Treat early scientific dialogue as a standing step in evidence planning, not an occasional favour. Choose one asset where a real-world evidence question is likely to matter to payers. Write that question down in payer language: population, comparator, outcome and data source. Then test it, whether through the MHRA-NICE route or any equivalent offered by another body. Keep the answer in your evidence plan and revisit it when national registries and HTA reports begin to move.